Healio

AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status

Please provide your email address to receive an email when new articles are posted on . An artificial intelligence-guided algorithm to identify cardiac amyloidosis received a breakthrough device ...
BioWorld

Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod

Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ...
Healio

AI accurately diagnosed cardiac amyloidosis on echocardiography

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...
FOX8 Cleveland

Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...
FierceBiotech

Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics

The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose ...
Business Wire

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with University of ...